Biotech: Page 28
-
hapabapa via Getty Images
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024 -
sanjeri via Getty Images
Sponsored by Quest DiagnosticsThe future of companion diagnostic (CDx) development: Why commercialization is key
As precision medicine expands into a growing number of therapeutic areas, the “one size fits all” approach to drug development is becoming less common.
March 25, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Sarah Silbiger via Getty Images
FDA clears first-of-its-kind Duchenne drug for broad use
The approval of Italfarmaco’s Duvyzat is the first for an oral, non-steroidal Duchenne drug and was issued for all patients at least six years of age, regardless of their genetic underpinnings.
By Ben Fidler • March 22, 2024 -
cagkansayin via Getty Images
NextCure to lay off 37% of staff, dial back research plans
The job cuts at the cancer biotech will primarily impact manufacturing roles, but will touch on several other parts of the organization too, the company said.
By Delilah Alvarado • March 21, 2024 -
Permission granted by Mirador Therapeutics
Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off
The financing for the startup, which is led by former executives of a biotech Merck recently bought for nearly $11 billion, is the sector’s largest for a privately held company this year.
By Gwendolyn Wu • March 21, 2024 -
Nemes Laszlo via Getty Images
Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise
The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.
By Ben Fidler • March 20, 2024 -
Peddalanka Ramesh Babu via Getty Images
Clasp launches with $150M and a plan for precision cancer immunotherapies
The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.
By Gwendolyn Wu • March 20, 2024 -
nopparit via Getty Images
Engrail’s precision psychiatry drugs get more buy in from venture investors
The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.
By Jacob Bell • March 19, 2024 -
Permission granted by Bluebird bio
Bluebird, short on cash, takes on $175M in debt financing
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
By Delilah Alvarado • March 18, 2024 -
PeopleImages via Getty Images
Sponsored by Cardinal Health Sonexus™ Access and Patient SupportThe digital divide: Balancing automation and human interaction regardless of the patient support program model
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
March 18, 2024 -
shutterstock.com/VAlekStudio
Sponsored by VeevaGive HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
JaysonPhotography via Getty Images
Contineum, a startup born from a Roche buyout, files for IPO
The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.
By Ben Fidler • March 17, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
By Ben Fidler • March 15, 2024 -
Love Employee via Getty Images
German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing
The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.
By Gwendolyn Wu • March 14, 2024 -
Permission granted by Novartis
IFM, an unorthodox biotech startup, scores third buyout with Novartis deal
With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million upfront and the potential for billions more in future payments.
By Kristin Jensen • March 13, 2024 -
Nemes Laszlo via Getty Images
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
By Ben Fidler • March 12, 2024 -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentAfter surprise trial failure, ALS doctors brace for one less treatment option
Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.
By Jacob Bell • Updated April 4, 2024 -
sudok1 via Getty Images
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
By Delilah Alvarado • March 11, 2024 -
Permission granted by Amylyx Pharmaceuticals
Q&AAmylyx CEOs look for a path forward following major setback
Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.
By Jacob Bell • March 11, 2024 -
hapabapa via Getty Images
Biotech stock fundings headed for best quarter in 3 years, Jefferies says
Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said.
By Ben Fidler • March 11, 2024 -
andresr via Getty Images
Sponsored by PurpleLabCan using SDoH data help identify patient populations who could benefit from weight loss drugs?
SDoH data can help companies understand the footprint of weight loss medications in the market and their impact across populations.
March 11, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Michael M. Santiago via Getty Images
Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO
The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.
By Gwendolyn Wu • March 7, 2024 -
Stadtratte via Getty Images
European VC Invivo readies its latest fund to back new biotechs
The Barcelona-based firm, which is targeting about 100 million euros for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.
By Gwendolyn Wu • March 6, 2024 -
Maximusnd via Getty Images
Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work
The startup, one of a number of young biotechs coming after Bristol Myers’ Sotyktu, will use the cash to fund a late-stage trial in plaque psoriasis.
By Delilah Alvarado • March 6, 2024
Previous
